Atreca Inc (NASDAQ:BCEL)
| 0.247 Delayed Data As of Dec 08 |  -0.0158 / -6.01%Today’s Change | 0.19 Today|||52-Week Range 2.05 | -69.15% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $8.4M |
Company Description
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.
Contact Information
Atreca, Inc. 835 Industrial Road San Carlos California 94070 |
Employees
Shareholders
| Mutual fund holders | 6.19% |
| Other institutional | 24.50% |
| Individual stakeholders | 14.80% |
Top Executives
| John A. Orwin | President, CEO, CFO & Director |
| Daniel Emerling | Senior Vice President-Research |
| Stephen Gould | Chief Scientific Officer |
| Philippe C. Bishop | Chief Medical Officer |
| Tito A. Serafini | Director & Chief Strategy Officer |
